NantHealth & NantOmics to Present Data on Three-Fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome ...
03 June 2018 - 7:03AM
Business Wire
Results to be presented during the tumor
biology session at the ASCO 2018 Annual Meeting
NantWorks, LLC today announced that its affiliate companies,
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company and NantOmics, LLC,
the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, the leader in molecular diagnostics and a
member of the NantWorks ecosystem of families, will present data on
three-fold overestimation of tumor mutation burden (TMB) using a
248 gene list as a panel to impute TMB during the tumor biology
session at the American Society of Clinical Oncology (ASCO) 2018
Annual Meeting, an event bringing together 30,000 oncology
professionals from June 1-5, 2018 at McCormick Place in Chicago,
Illinois. NantWorks will be exhibiting at booth #7147 during the
event.
The data presented here have significant implications on the use
of immunotherapies such as Keytruda and Opdivo given previous data
touting the effectiveness of these drugs in patients whose tumors
bear high TMB. The NantWorks companies’ data presented here caution
against overestimation of TMB and thus immunotherapy overuse when
extrapolating TMB from smaller panel tests (<500 genes) versus
simply identifying all actual mutations by surveying the entire
genome. Further, whether performing analysis on the entire genome
or in a panel test, clinical validity for the use of
immunotherapies is made appreciably more precise by confirming the
expression of identified mutations. The patient’s immune system
recognizes and targets non-self proteins, not DNA, thus
underscoring the need to append the mutated genomic data with
expression data. Maximal accuracy as established in this
presentation by the use of tumor-normal DNA interpretation of TMB
from surveying all genes and further amplified by derivation of
expressed TMB is what is required for future immunotherapies such
as neoepitope vaccines.
“We’re excited to share our data from our retrospective
analysis, which may impact ICT prescription and expectation of
clinical benefit,” said Patrick Soon-Shiong, MD, founder of
NantWorks. “Our analysis builds on our breadth of actionable
insight and molecularly driven support for cancer patients and
their providers, and we look forward to continuing to build upon
our diagnostic capabilities.”
Presentation Details
Three-fold overestimation of tumor mutation burden using 248
gene panel versus whole exome, Abstract,
#12117WHO: NantHealth, LLC and NantOmics,
LLCWHAT: Tumor Biology SessionWHEN: June 4, 1:15-4:45
PM CSTWHERE: Hall A, McCormick Place
Presentation Summary
This study analyzed if actual TMB (aTMB), consisting of
mutations across the exome, and expressed TMB (eTMB), consisting of
expressed genes, would differ substantially from iTMB.
Retrospective analysis of a database from a commercial DNA
tumor:normal and RNAseq platform was carried out. 890 clinical
samples were analyzed, composing of both primary and metastatic
disease by whole genome sequencing (WGS) or WES and RNA sequencing
(RNA-Seq), and compared true tumor mutational burden to a predicted
tumor mutational burden from a list of 248 genes thought to drive
cancer. The study showed an estimated tumor mutational burden based
only on the list of 248 genes had an average of 15.79 mutations per
megabase whereas WGS/WES derived TMB had an average of 5.09
mutations per megabase of coding DNA. As a result, the study
indicates that a roughly 3-fold over-estimate of TMB was observed,
which may impact ICT prescription and expectation of clinical
benefit.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular diagnostic capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular diagnostics company to
pioneer an integrated approach to unearthing the genomic and
proteomic variances that initiate and drive cancer, by analyzing
both normal and tumor cells from the same patient and following
identified variances through from DNA to RNA to protein to drug.
NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing
genomic variances in near real-time, and correlating proteomic
pathway analysis with quantitative multi-plexed protein expression
analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please
visit www.nantomics.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180602005095/en/
NANTJen Hodsonjhodson@nantworks.comorNANTHenry C.
Jacksoncj@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024